Circulating Tumor Cells (CTC) in Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood samples: Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.

Samples from tumor draining vessels: In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.

Study summary

This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Eligibility

Primary outcome measure(s)

• Overall survival (OS) in heterogeneous cancer population — Screening (Visit 1) until the date of death (assessed up to 240 months)
  overall survival (OS) in heterogeneous cancer population
• Change in total number of isolated CTCs — Through study completion, an average of 20 years
  Change in total number of isolated CTCs

Trial sites (2)

More University Hospital, Basel, Switzerland trials in Switzerland

Other trials for the same condition